2.11

0.47% -0.01

After Hours: 2.0408 -0.0692 -3.28%

InspireMD Inc. (NSPR)

Overview News Price History Option Chain Discussions Forecast Stock Split

InspireMD Inc. stock is currently priced at $2.11, with a 24-hour trading volume of 7,232. It has seen a -0.47% decreased in the last 24 hours and a -9.93% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.10 pivot point. If it approaches the $2.24 resistance level, significant changes may occur.

Previous Close:

$2.12

Open:

$2.1

24h Volume:

7,232

Market Cap:

$49.43M

Revenue:

$6.21M

Net Income/Loss:

$-19.92M

P/E Ratio:

-1.0821

EPS:

-1.95

Net Cash Flow:

$-16.76M

1W Performance:

+8.01%

1M Performance:

-9.93%

6M Performance:

-34.88%

1Y Performance:

+43.05%

1D Range:

$2.10

$2.23

52W Range:

$1.2951

$3.85

InspireMD Inc. Stock (NSPR) Company Profile

Name

InspireMD Inc.

Sector

Healthcare (1217)

Industry

Medical Devices (160)

Phone

972 3 6917691

Address

4 Menorat Hamaor Street, Tel Aviv

Employee

Twitter

@InspireMD

Next Earnings Date

2024-05-14

Latest SEC Filings

NSPR's Discussions on Twitter

InspireMD Inc. Stock (NSPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-16	Initiated	Rodman & Renshaw	Buy
Mar-13-15	Downgrade	Oppenheimer	Outperform → Perform
Nov-26-13	Initiated	Oppenheimer	Outperform

InspireMD Inc. Stock (NSPR) Latest News

Shockwave Medical (SWAV) Q1 Earnings and Revenues Top Estimates

Zacks Investment Research

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

GlobeNewswire Inc.

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

GlobeNewswire Inc.

InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS

Zacks Investment Research

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

GlobeNewswire Inc.

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

GlobeNewswire Inc.

InspireMD Inc. Stock (NSPR) Financials Data

InspireMD Inc. (NSPR) Revenue 2024

NSPR reported a revenue (TTM) of $6.21 million for the quarter ending December 31, 2023, a +20.00% rise year-over-year.

InspireMD Inc. (NSPR) Net Income 2024

NSPR net income (TTM) was -$19.92 million for the quarter ending December 31, 2023, a -7.71% decrease year-over-year.

InspireMD Inc. (NSPR) Cash Flow 2024

NSPR recorded a free cash flow (TTM) of -$16.76 million for the quarter ending December 31, 2023, a -4.63% decrease year-over-year.

InspireMD Inc. (NSPR) Earnings per Share 2024

NSPR earnings per share (TTM) was -$1.05 for the quarter ending December 31, 2023, a +55.13% growth year-over-year.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.